CTKB — Cytek Biosciences, Inc.
—
Nasdaq ·
Unknown ·
Unknown ·
CIK 1831915 ·
Last close
$4.22
Market Cap
$544.98M
52W High
$4.99
52W Low
$3.31
ADV30
1,583,697
Next earnings
2026-08-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 44,135,000 | 21,254,000 | -18,463,000 | -18,866,000 | 449,113,000 | 65,665,000 | 121,469,000 |
| Dec 2025 | 62,141,000 | 32,885,000 | -5,594,000 | -44,076,000 | 461,542,000 | 90,853,000 | 119,803,000 |
| Sep 2025 | 52,293,000 | 27,551,000 | -9,192,000 | -5,478,000 | 494,919,000 | 93,281,000 | 116,348,000 |
| Jun 2025 | 45,602,000 | 23,867,000 | -10,624,000 | -5,583,000 | 493,320,000 | 75,470,000 | 115,763,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-4,686,000
Investing CF
$10,118,000
Financing CF
$-13,433,000
CapEx
$-4,190,000
Dividends Paid
—
Buybacks
$-15,074,000
EPS Diluted TTM
$-0.51
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-101,738,000
Inventory
$48,428,000
Receivables
$72,127,000
ST Investments
$170,676,000
EBIT TTM
$-29,367,000
Pretax Income TTM
$-29,841,000
Interest Exp TTM
$474,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$204,171,008
EBITDA
$-36,303,000
Free Cash Flow
$6,412,875
Enterprise Value
$310,238,720
Total Cash
$262,224,992
Total Debt
$27,482,000
Shares Out
129,142,587
Trailing EPS
$-0.58
Book Value
$2.54
ROE
-20.9%
ROA
-5.9%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 201,493,000 | -40,384,000 | -66,539,000 | 461,542,000 | 119,803,000 | — | -4,686,000 |
| Dec 2024 | 200,453,000 | -20,523,000 | -6,020,000 | 499,500,000 | 103,763,000 | — | 25,379,000 |
| Dec 2023 | 193,015,000 | -27,845,000 | -12,148,000 | 494,457,000 | 101,393,000 | — | 5,281,000 |
| Dec 2022 | 164,036,000 | -1,804,000 | 2,576,000 | 519,476,000 | 93,930,000 | — | -12,231,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.20
Max Pain — expiry 2026-10-16 (volume-derived — Yahoo OI feed degraded)
max pain strike: $2.50 · spot: $4.22 · call volume: 5 · put volume: 1
Expected Move to 2026-10-16:
±$2.88
(68.25%) —
implied range
$1.34 –
$7.10
· ATM straddle on $5.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AVK | ADVENT CONVERTIBLE & INCOME FUND | $546.56M | $12.38 | — |
| EROK | EagleRock Land, LLC | $547.56M | $22.39 | — |
| VGM | Invesco Trust for Investment Grade Municipals | $547.74M | $10.10 | — |
| MMU | WESTERN ASSET MANAGED MUNICIPALS FUND INC. | $547.83M | $10.03 | — |
| DAO | Youdao, Inc. | $548.46M | $16.80 | — |
News headlines (Yahoo Finance, 1h cache)
Analysts Estimate Cytek Biosciences, Inc. (CTKB) to Report a Decline in Earnings: What to Look Out for
2026-07-29 14:00 · Yahoo
CSBR vs. CTKB: Which Life Sciences Stock Has Better Long-Term Upside?
2026-07-23 17:19 · Yahoo
Cytek Biosciences to Report Second Quarter 2026 Financial Results on August 5, 2026
2026-07-22 20:05 · Yahoo
Cytek® Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement
2026-07-15 21:00 · Yahoo
Cytek Biosciences (CTKB) Stock Sees Fair Value Falls After Analysts Cut Targets
2026-06-17 07:14 · Yahoo
Cytek Biosciences to participate at the Singular Research’s Las Vegas Invitational Conference
2026-06-10 20:05 · Yahoo
Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
2026-06-05 23:25 · Yahoo
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
2026-06-02 21:00 · Yahoo
Promising Penny Stocks To Consider In June 2026
2026-06-01 18:05 · Yahoo
Prenetics Starts Partnership with Jay Shetty as IM8 Global Ambassador & Shareholder
2026-05-20 20:51 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.